Research Team (IMAGE)
Caption
The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer. This public-private collaboration enabled researchers identify molecular mechanisms underlying the lack of efficiency of this drug in squamous cell carcinoma, a sub-type of non-small cell lung cancer, and the important role of smoking in this lack of effectivity.
Credit
Xènia Fuentes/UB
Usage Restrictions
You may state that the image may only be used with appropriate caption or credit.
License
Licensed content